Steril-eeze alcohol-free hand sanitiser offers hygiene companion for travellers
By Luke Barras-hill |
UK-based consumer healthcare firm East Midlands Pharma (EM Pharma) has introduced the Steril-eeze Anti Viral Travel Sanitiser.
The alcohol-free, Hypochlorous-based product claims to kill 99.99% of viruses and bacteria and can be used for hands, surfaces and face masks.
It is available in a hand-luggage sized 50ml (RSP £2.79/$3.83), 100ml (RSP £3.99) and 250ml spray bottle (RSP £7.49).
EM Pharma, a subsidiary of independent pharmacy chain the Day Lewis Group of Companies, believes there are opportunities to introduce new products into the market after the launch of Steril-eeze ‘Kind to Hands’ last year.
‘GOLD STANDARD’ MISSION
Quoting figures from global analytics and data firm Nielsen, EM Pharma says the sanitiser market grew from £11.7 million in 2019 to £120.5 million in 2020.
Paul Walsh, Managing Director, EM Pharma said: “As we see travel restrictions being lifted, consumers will next be looking for a sanitiser that fulfils all their travel hygiene needs, whether they’re commuting to the office, holidaying in the UK, or flying short or long haul. Steril-eeze Anti Viral Travel ticks all the boxes.
“Our mission for the Steril-eeze brand has always been to produce the gold standard in alcohol-free sanitiser alternatives and this latest travel extension to the core range shows we’re here for the duration.”
‘Go further with collaboration’, hear attendees
TR Sustainability Week 2023 live sessions kicked off on Tuesday* (5 September) with keynote...
The Sustainability Pitch Session 1: Chilly's
TRBusiness is delighted to announce the first Sustainability Pitch session of Travel Retail...
Blueprint hails True Gum GTR growth as brand gains B-Corporation status
Travel retail business development agency Blueprint is celebrating growing momentum for...
-
International,
‘Go further with collaboration’, hear attendees
-
International,
The Sustainability Pitch Session 1: Chilly's
-

In the Magazine
TRBusiness Magazine is free to access. Read the latest issue now.